Previous 10 | Next 10 |
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products PR Newswire HOLON, Israel , Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clini...
Compugen to Present at Upcoming Investor Conferences PR Newswire HOLON, Israel, Nov. 10, 2020 HOLON, Israel , Nov. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target dis...
The following slide deck was published by Compugen Ltd. in conjunction with their 2020 Q3 earnings call. For further details see: Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Compugen has concentrated exposure to immuno-oncology, where it has formed key collaborations with large players in early-stage studies. Shareholders have seen +119% upside YTD; however, accurate valuation is difficult at present due to uncertainty of future cash flows and pipeline co...
Start Time: 08:30 End Time: 09:25 Compugen Ltd. (CGEN) Q3 2020 Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO Henry Adewoye - SVP and CMO Ari Krashin - CFO and COO Eran Ophir - VP, Research and Drug Discovery Elana Holzman - D...
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN) Q3 2020 Earnings Call Nov 5, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Compugen Ltd. (CGEN) Q3 2020 Earnings Call Transcript
[[AAON]], [[AAWW]], [[ABC]], [[ACIW]], [[AEIS]], [[AGIO]], [[ALNY]], [[AMRN]], [[AZN]], [[BABA]], [[BCE]], [[BDX]], [[BLL]], [[BMY]], [[CAH]], [[CCOI]], [[CEVA]], [[CGEN]], [[CHH]], [[CI]], [[CNK]], [[CNP]], [[CNQ]], [[COMM]], [[CORE]], [[CPRI]], [[CRON]], [[CWEN]], [[D]], [[DISCA]], [[DNB]],...
Compugen (NASDAQ:CGEN) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is -$0.09 (+10.0% Y/Y)Over the last 1 year, CGEN has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time.Over the last...
Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China New patent expands composition of matter and use protection for COM902 beyond the United States and Europe PR Newswire HOLON, Israel, Nov. 2, 2020 HOLO...
Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy Expression data suggest potential of PVRIG inhibition to enhance T cell priming and infiltration into both inflamed and less inflamed tumors Data further s...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...